3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
32
CNS
21
Lymphoid
8
Dermatologic
7
Genitourinary
6
Gastrointestinal
6
Endocrine
3
Thoracic
2
Other solid neoplasm
2
Head & Neck
2
Plasma cell
1
Other hematologic neoplasm
1
NET
1
Gynecologic
1
Breast
1
Conditions
Neuroendocrine Tumors
117
Gastro-enteropancreatic neuroendocrine tumor
21
Neoplasms
20
Carcinoid Tumor
17
Colorectal Neoplasms
13
Carcinoma, Neuroendocrine
11
Neoplasm Metastasis
10
Carcinoma
10
Lung Neoplasms
9
Small Cell Lung Carcinoma
8
Prostatic Neoplasms
8
Carcinoma, Renal Cell
8
Carcinoma, Non-Small-Cell Lung
8
Breast Neoplasms
8
Sarcoma
7
Pancreatic Neoplasms
7
Carcinoma, Hepatocellular
7
Adenoma, Islet Cell
7
Stomach Neoplasms
6
Serotonin Syndrome
6
Pheochromocytoma
6
Melanoma
6
Head and Neck Neoplasms
6
Digestive System Neoplasms
6
Cholangiocarcinoma
6
Thyroid Neoplasms
5
Paraganglioma
5
Ovarian Neoplasms
5
Gastroenteropancreatic Neuroendocrine Tumors
5
Colonic Neoplasms
5
Interventions
amino-acid, glucose, and electrolyte solution
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Rhabdomyosarcoma
×
NET
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled